{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:41:43Z","timestamp":1788576103195,"version":"build-2803163510"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jsbmb.2021.105808","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T03:03:20Z","timestamp":1610161400000},"page":"105808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies"],"prefix":"10.1016","volume":"207","author":[{"given":"Nikolaos","family":"Nikolaou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy W.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2021.105808_bib0005","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/bies.20792","article-title":"What goes on behind closed doors: physiological versus pharmacological steroid hormone actions","volume":"30","author":"Simons","year":"2008","journal-title":"BioEssays."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrendo.2009.212","article-title":"Testosterone deficiency, insulin resistance and the metabolic syndrome","author":"Zitzmann","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0015","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2337\/dc10-2339","article-title":"Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes","volume":"34","author":"Wang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4602129","article-title":"Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health","author":"Golds","year":"2017","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0025","doi-asserted-by":"crossref","unstructured":"A. Barthel, H.S. Willenberg, M. Gruber, S.R. Bornstein, Chapter 102 - Adrenal Insufficiency, J.L. Jameson, L.J. De Groot, D.M. de Kretser, L.C. Giudice, A.B. Grossman, S. Melmed, J.T. Potts, G.C.B.T.-E.A. and P. (Seventh E. Weir (Eds.), W.B. Saunders, Philadelphia, 2016: pp. 1763-1774.e4. doi:https:\/\/doi.org\/10.1016\/B978-0-323-18907-1.00102-5.","DOI":"10.1016\/B978-0-323-18907-1.00102-5"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000493239","article-title":"Hyponatremia and glucocorticoid deficiency","author":"Garrahy","year":"2019","journal-title":"Front. Horm. Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0035","first-page":"1022","article-title":"Cortisol metabolism in human obesity: impaired cortisone--&cortisol conversion in subjects with central adiposity","volume":"84","author":"Stewart","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0040","doi-asserted-by":"crossref","first-page":"41293","DOI":"10.1074\/jbc.M103676200","article-title":"Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice","volume":"276","author":"Morton","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0045","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s00125-002-0959-6","article-title":"Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice","volume":"45","author":"Alberts","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0050","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1210\/en.2003-0344","article-title":"Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains","volume":"144","author":"Alberts","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0055","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543784.2010.504713","article-title":"11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes","volume":"19","author":"Morgan","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0060","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s00125-014-3240-x","article-title":"Hepatic 11beta-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique","volume":"57","author":"Dube","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0065","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.2337\/db08-0495","article-title":"Impaired glucose tolerance and insulin resistance are associated with increased adipose 11\u03b2-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5\u03b1-reductase activity","volume":"57","author":"Tomlinson","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105439","article-title":"Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review","author":"Schiffer","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0075","doi-asserted-by":"crossref","DOI":"10.1515\/jpem.2010.059","article-title":"Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene","author":"Nagaraja","year":"2010","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0080","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-10-0930","article-title":"Recognition of 5\u03b1-reductase-2 deficiency in an adult female 46XY DSD clinic","author":"Berra","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0085","article-title":"Separation of delta 4-5 alpha-hydrogenases from rat liver homogenates","author":"Dorfman","year":"1956","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0090","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1073\/pnas.87.10.3640","article-title":"Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases","volume":"87","author":"Andersson","year":"1990","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1172\/JCI115574","article-title":"Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase","volume":"89","author":"Jenkins","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0100","article-title":"Deletion of steroid 5\u03b1-reductase 2 gene in male pseudohermaphroditism","author":"Andersson","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","article-title":"Steroid 5alpha-Reductase: two genes \/ two enzymes","volume":"63","author":"Russell","year":"1994","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0110","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/530121","article-title":"The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases","author":"Azzouni","year":"2012","journal-title":"Adv. Urol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/0960-0760(92)90297-V","article-title":"Cortisol metabolism by human liver in vitro-I. Metabolite identification and inter-individual variability","author":"Abel","year":"1992","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cbi.2011.01.019","article-title":"Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids","author":"Jin","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0125","doi-asserted-by":"crossref","DOI":"10.1210\/er.2018-00089","article-title":"Structural and functional biology of aldo-keto reductase steroid-transforming enzymes","author":"Penning","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygcen.2009.08.004","article-title":"Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase","volume":"166","author":"Langlois","year":"2010","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)42482-9","article-title":"Four-amino acid segment in steroid 5\u03b1-reductase 1 confers sensitivity to finasteride, a competitive inhibitor","author":"Thigpen","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19249-z","article-title":"Structure of human steroid 5\u03b1-reductase 2 with the anti-androgen drug finasteride","author":"Xiao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI116665","article-title":"Tissue distribution and ontogeny of steroid 5\u03b1-reductase isozyme expression","author":"Thigpen","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygcen.2009.12.010","article-title":"Cloning and differential expression of steroid 5\u03b1-reductase type 1 (Srd5a1) and type 2 (Srd5a2) from the Harderian glands of hamsters","author":"Ramos","year":"2010","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0155","first-page":"3316","article-title":"Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases","volume":"84","author":"Finken","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0160","doi-asserted-by":"crossref","DOI":"10.1161\/01.HYP.33.6.1364","article-title":"Cortisol effects on body mass, blood pressure, and cholesterol in the general population","author":"Fraser","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0165","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/jcem.83.5.4951","article-title":"Obesity and gender influence cortisol secretion and metabolism in man","volume":"83","author":"Andrew","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0170","doi-asserted-by":"crossref","DOI":"10.1006\/bbrc.1995.2530","article-title":"Expression of the type 1 and type 2 steroid 5\u03b1-reductases in human fetal tissues","author":"Ellsworth","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.juro.2007.03.089","article-title":"Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development","volume":"178","author":"Lunacek","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/JOE-11-0318","article-title":"5\u03b1-Reduced glucocorticoids: a story of natural selection","volume":"212","author":"Nixon","year":"2012","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2016.02.003","article-title":"Characterization of 5\u03b1-reductase activity and isoenzymes in human abdominal adipose tissues","author":"Fouad Mansour","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/pros.21318","article-title":"5\u03b1-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression","author":"Godoy","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0195","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1515\/HMBCI.2010.035","article-title":"Human type 3 5\u03b1-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride","volume":"2","author":"Yamana","year":"2010","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2014.11.005","article-title":"Hamster SRD5A3 lacks steroid 5\u03b1-reductase activity in vitro","author":"Ch\u00e1vez","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cell.2010.06.001","article-title":"SRD5A3 is required for converting polyprenol to Dolichol and is mutated in a congenital glycosylation disorder","volume":"142","author":"Cantagrel","year":"2010","journal-title":"Cell."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0210","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awq261","article-title":"A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism","author":"Morava","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0215","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2010.132","article-title":"Next generation sequencing in a family with autosomal recessive Kahrizi syndrome (OMIM 612713) reveals a homozygous frameshift mutation in SRD5A3","author":"Kahrizi","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0220","article-title":"Phenotypic expansion of congenital disorder of glycosylation due to SRD5A3 null mutation","author":"Tuysuz","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0225","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.37875","article-title":"SRD5A3-CDG: Expanding the phenotype of a congenital disorder of glycosylation with emphasis on adult onset features","author":"Wheeler","year":"2016","journal-title":"Am. J. Med. Genet. Part A."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0230","article-title":"Identification of a case of SRD5A3-congenital disorder of glycosylation (CDG1Q) by exome sequencing, Indian","author":"Gupta","year":"2018","journal-title":"J. Med. Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0235","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1021\/bi00072a028","article-title":"Finasteride: a slow-binding 5 alpha-reductase inhibitor","volume":"32","author":"Faller","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0240","first-page":"139","article-title":"Evaluation of men on finasteride","volume":"14","author":"Gormley","year":"1996","journal-title":"Semin. Urol. Oncol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.1997.950908.x","article-title":"Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia","volume":"46","author":"Habib","year":"1997","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0250","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0090-4295(99)80021-1","article-title":"Treatment with finasteride following radical prostatectomy for prostate cancer","volume":"45","author":"Andriole","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0255","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/ja953069t","article-title":"Mechanism-Based inhibition of human steroid 5\u03b1-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor","volume":"118","author":"Bull","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0260","doi-asserted-by":"crossref","DOI":"10.1517\/14656566.6.2.311","article-title":"Dutasteride: a novel dual inhibitor of 5\u03b1-reductase for benign prostatic hyperplasia","author":"Djavan","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)43378-9","article-title":"Inhibition of 5\u03b1-reductase, receptor binding, and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid","author":"Liang","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.steroids.2009.10.005","article-title":"An overview on 5alpha-reductase inhibitors","volume":"75","author":"Aggarwal","year":"2010","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000246242","article-title":"The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders","volume":"193","author":"Chen","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2003.10.004","article-title":"Selective non-steroidal inhibitors of 5 alpha-reductase type 1","volume":"88","author":"Occhiato","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0285","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1248\/cpb.49.1081","article-title":"New progesterone esters as 5alpha-reductase inhibitors","volume":"49","author":"Cabeza","year":"2001","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0290","doi-asserted-by":"crossref","first-page":"E1397","DOI":"10.1210\/jc.2014-1395","article-title":"5alpha-reductase type 1 modulates insulin sensitivity in men","volume":"99","author":"Upreti","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2014.04.008","article-title":"Understanding androgen action in adipose tissue","volume":"143","author":"O\u2019Reilly","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0300","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.2008.03262.x","article-title":"Depot-specific steroidogenic gene transcription in human adipose tissue","author":"MacKenzie","year":"2008","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0305","article-title":"Androgens and body fat distribution, J. Steroid Biochem","author":"Blouin","year":"2008","journal-title":"Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0310","doi-asserted-by":"crossref","DOI":"10.1007\/s13679-014-0119-6","article-title":"Androgens, body fat distribution and Adipogenesis","author":"Zerradi","year":"2014","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0315","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mce.2008.09.034","article-title":"Progesterone metabolism in adipose cells","volume":"298","author":"Zhang","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0320","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1210\/endo-111-1-136","article-title":"Multihormonal control of microsomal 5\u03b1-reductase activity in cultured adult female rat hepatocytes","volume":"111","author":"Ann Miller","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0325","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/endo.133.2.8344190","article-title":"Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I","volume":"133","author":"Horton","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0330","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1507\/endocrj.51.37","article-title":"Steroid 5alpha reductase mRNA type 1 is differentially regulated by androgens and glucocorticoids in the rat liver","volume":"51","author":"El-Awady","year":"2004","journal-title":"Endocr. J."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0335","doi-asserted-by":"crossref","DOI":"10.1210\/en.2015-1149","article-title":"5\u03b1-reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes","volume":"156","author":"Nasiri","year":"2015","journal-title":"Endocrinology."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0340","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/oby.2005.186","article-title":"Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization","volume":"13","author":"Livingstone","year":"2005","journal-title":"Obes. Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0345","doi-asserted-by":"crossref","DOI":"10.1210\/en.2004-1063","article-title":"Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats","author":"Drake","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0350","doi-asserted-by":"crossref","DOI":"10.1002\/j.1550-8528.1994.tb00090.x","article-title":"The male obese wistar diabetic fatty rat is a new model of extreme insulin resistance","author":"Greene","year":"1994","journal-title":"Obes. Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0355","doi-asserted-by":"crossref","DOI":"10.1210\/en.2013-1592","article-title":"Loss of 5\u03b1-Reductase Type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice","volume":"154","author":"Dowman","year":"2013","journal-title":"Endocrinology."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0360","doi-asserted-by":"crossref","DOI":"10.2337\/db14-0249","article-title":"5\u03b1-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis and liver fibrosis in rodents","volume":"64","author":"Livingstone","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0365","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2337\/db08-0094","article-title":"Reduced glucocorticoid production rate, decreased 5\u03b1-reductase activity, and adipose tissue insulin sensitization after weight loss","volume":"57","author":"Tomlinson","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0370","first-page":"3330","article-title":"Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity","volume":"87","author":"Rask","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0375","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1210\/jc.2002-020048","article-title":"Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance","volume":"87","author":"Andrews","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0380","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2265.2008.03358.x","article-title":"Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis","volume":"70","author":"Konopelska","year":"2009","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0385","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s00125-007-0629-9","article-title":"Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men","volume":"50","author":"Holt","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0390","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1210\/jc.2003-030596","article-title":"Body fat distribution and cortisol metabolism in healthy men: enhanced 5\u03b2-reductase and lower ccortisol\/cortisone metabolite ratios in men with fatty liver","volume":"88","author":"Westerbacka","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029531","article-title":"A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease","volume":"7","author":"Ahmed","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0400","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/eje.0.1500185","article-title":"Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men","volume":"150","author":"Johnstone","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0405","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1210\/jc.2007-0692","article-title":"Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men","volume":"92","author":"Stimson","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0410","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-4120","article-title":"Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT)","author":"Woods","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0415","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2015-2928","article-title":"Dual-5\u03b1-reductase inhibition promotes hepatic lipid accumulation in man","volume":"101","author":"Hazlehurst","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0420","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa408","article-title":"Co-administration of 5\u03b1-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids","author":"Othonos","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0425","article-title":"Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction","volume":"30","author":"Traish","year":"2017","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0430","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l1204","article-title":"Incidence of type 2 diabetes mellitus in men receiving steroid 5\u03b1-reductase inhibitors: population based cohort study","author":"Wei","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0435","article-title":"Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients","author":"Rossi","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0440","article-title":"Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search","author":"Moribe","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0445","article-title":"Preventive effect of FK143, a 5\u03b1-reductase inhibitor, on chemical hepatocarcinogenesis in rats","author":"Maruyama","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(07)61345-2","article-title":"Polycystic ovary syndrome","author":"Norman","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0455","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/jc.2005-2774","article-title":"Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome","volume":"91","author":"Setji","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0460","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tem.2007.07.004","article-title":"Pathophysiology and types of dyslipidemia in PCOS","volume":"18","author":"Diamanti-Kandarakis","year":"2007","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0465","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2007.04.012","article-title":"Nonalcoholic fatty liver disease in women with polycystic ovary syndrome","volume":"47","author":"Cerda","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0470","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.3748\/wjg.v20.i26.8351","article-title":"Nonalcoholic fatty liver disease and polycystic ovary syndrome","author":"Vassilatou","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0475","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1210\/jc.2006-0227","article-title":"Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women","volume":"91","author":"Goodarzi","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0480","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejogrb.2011.03.026","article-title":"Association of genetic variants in the two isoforms of 5??-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome","volume":"157","author":"Graupp","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0485","first-page":"2414","article-title":"5alpha-reductase activity in women with polycystic ovary syndrome","volume":"84","author":"Jakimiuk","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0490","first-page":"67","article-title":"Evaluation of 5\u03b1-reductase activity on cultured fibroblast in patients with hyperandrogenemia","volume":"47","author":"Boda","year":"2009","journal-title":"Rom.J.Intern.Med."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0495","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0140-6736(90)90664-Q","article-title":"5 \u03b1lpha-reductase activity in polycystic ovary syndrome","volume":"335","author":"Stewart","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0500","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1515\/JPEM.2000.13.3.253","article-title":"Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome","volume":"13","author":"Chin","year":"2000","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0505","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1210\/jc.2003-030240","article-title":"Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates","volume":"88","author":"Tsilchorozidou","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0510","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1210\/jc.2002-021875","article-title":"Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome","volume":"88","author":"Fassnacht","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0515","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1210\/jc.2009-0837","article-title":"Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome","volume":"94","author":"Vassiliadi","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0520","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/jc.2015-3926","article-title":"Evidence for increased 5\u03b1-Reductase activity during early childhood in daughters of women with polycystic ovary syndrome","volume":"101","author":"Torchen","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0525","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJM199402173300703","article-title":"Hyperandrogenism in polycystic ovary syndrome -- evidence of dysregulation of 11\u03b2-Hydroxysteroid dehydrogenase","volume":"330","author":"Rodin","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0530","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF03346454","article-title":"Increased clearance of cortisol by 5\u03b2-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome","volume":"32","author":"Gambineri","year":"2009","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0535","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jc.2013-3399","article-title":"Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione","volume":"99","author":"O\u2019Reilly","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0540","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12958-017-0242-9","article-title":"5\u03b1-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"15","author":"Wu","year":"2017","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0545","article-title":"Exercise activates the PI3K-AKT signal pathway by decreasing the expression of 5\u03b1-reductase type 1 in PCOS rats","author":"Wu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0550","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8405796","article-title":"Effects of exercise combined with finasteride on hormone and ovarian function in polycystic ovary syndrome rats","author":"Wu","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0555","doi-asserted-by":"crossref","DOI":"10.1530\/eje.0.1410361","article-title":"Comparison of finasteride versus flutamide in the treatment of hirsutism","author":"Falsetti","year":"1999","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0560","doi-asserted-by":"crossref","DOI":"10.1016\/S0015-0282(16)58388-5","article-title":"Finasteride in the treatment of hirsutism: new therapeutic perspectives","author":"Tolino","year":"1996","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpag.2013.09.010","article-title":"Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study","author":"Tartagni","year":"2014","journal-title":"J. Pediatr. Adolesc. Gynecol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2009.01.150","article-title":"Effect of finasteride on ovulation induction in nonresponder (hyperandrogenic) polycystic ovary syndrome (PCOS) women","author":"Tartagni","year":"2010","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0575","article-title":"Comparison of finasteride, metformin, and finasteride plus metformin in PCOS","author":"Diri","year":"2017","journal-title":"Acta Endocrinol. (Copenh)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0580","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-1040","article-title":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study","author":"Ganie","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0585","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2005-2250","article-title":"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study","author":"Gambineri","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0590","doi-asserted-by":"crossref","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: Consequences of endogenous and exogenous excess and replacement therapy","author":"Hardy","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0595","article-title":"Estrogen and bone metabolism","author":"V\u00e4\u00e4n\u00e4nen","year":"1996","journal-title":"Maturitas."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0600","doi-asserted-by":"crossref","DOI":"10.1038\/nrendo.2013.179","article-title":"The role of estrogen and androgen receptors in bone health and disease","author":"Manolagas","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0605","article-title":"Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism","author":"Katznelson","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0610","first-page":"258","article-title":"Testosterone metabolism in human bone","volume":"95","author":"Schweikert","year":"1980","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0615","first-page":"101","article-title":"Androstenedione metabolism in cultured human osteoblast-like cells","volume":"75","author":"Bruch","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0620","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1210\/jc.2001-011902","article-title":"Human osteoblast-like cells express predominantly steroid 5\u03b1-reductase type 1","volume":"87","author":"Issa","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0625","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1111\/j.1582-4934.2009.00729.x","article-title":"Intracrine androgenic apparatus in human bone marrow stromal cells","volume":"13","author":"Sillat","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0630","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/endo.136.4.7895648","article-title":"Bone density is normal in male rats treated with finasteride","volume":"136","author":"Rosen","year":"1995","journal-title":"Endocrinology."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021402","article-title":"Reduced bone mass and muscle strength in male 5\u03b1-reductase type 1 inactivated mice","volume":"6","author":"Windahl","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0640","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2265.1992.tb02355.x","article-title":"Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism","volume":"37","author":"Matzkin","year":"1992","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0645","first-page":"1031","article-title":"Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study","volume":"81","author":"Tollin","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0650","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0022-5347(05)65095-1","article-title":"The long-term effect of specific type II 5\u03b1-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial","volume":"167","author":"Matsumoto","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0655","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.juro.2008.01.145","article-title":"The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men","volume":"179","author":"Amory","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0660","first-page":"835","article-title":"The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia","volume":"38","author":"Macukat","year":"2014","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0665","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1210\/jc.2005-2809","article-title":"Bone mineral density in the complete androgen insensitivity and 5\u03b1-reductase-2 deficiency syndromes","volume":"91","author":"Sobel","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0670","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1210\/jc.2003-031110","article-title":"Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone","volume":"89","author":"Amory","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0675","doi-asserted-by":"crossref","first-page":"E433","DOI":"10.1152\/ajpendo.00592.2013","article-title":"Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial","volume":"306","author":"Borst","year":"2014","journal-title":"AJP Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0680","doi-asserted-by":"crossref","DOI":"10.1089\/neu.2016.4814","article-title":"Testosterone plus finasteride prevents bone loss without prostate growth in a rodent spinal cord injury model","author":"Yarrow","year":"2017","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0685","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MAJ.0b013e3182a2169c","article-title":"The association of alpha-blockers and 5-alpha reductase inhibitors in benign prostatic hyperplasia with fractures","volume":"347","author":"Lim","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140598","article-title":"Risk of fractures and falls during and after 5\u03b1- reductase inhibitor use: a Nationwide Cohort Study","volume":"10","author":"Robinson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0695","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/13685538.2015.1072155","article-title":"Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study","volume":"19","author":"Wada","year":"2016","journal-title":"Aging Male"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0700","doi-asserted-by":"crossref","DOI":"10.1007\/s002239900106","article-title":"Aromatization of androgens is important for skeletal maintenance of aged male rats","author":"Vanderschueren","year":"1996","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0705","doi-asserted-by":"crossref","DOI":"10.1359\/jbmr.2000.15.3.507","article-title":"Bone has a sexually dimorphic response to aromatase deficiency","author":"\u00d6z","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0710","doi-asserted-by":"crossref","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","author":"Falahati-Nini","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0715","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cen.12599","article-title":"A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia","volume":"82","author":"Lin","year":"2015","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2005.09.004","article-title":"Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5\u03b1-reductase inhibitor","author":"Ishikawa","year":"2006","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0725","doi-asserted-by":"crossref","DOI":"10.1080\/13685538.2018.1482487","article-title":"The relationship between circulating testosterone and inflammatory cytokines in men","author":"Mohamad","year":"2019","journal-title":"Aging Male"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0730","doi-asserted-by":"crossref","first-page":"22908","DOI":"10.1074\/jbc.M402822200","article-title":"5\u03b1-reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor","volume":"279","author":"McInnes","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0735","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/j.1476-5381.2011.01465.x","article-title":"5\u03b1-reduced glucocorticoids exhibit dissociated anti-inflammatory and metabolic effects","volume":"164","author":"Yang","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0740","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0742-8413(97)00207-7","article-title":"Sex steroid hormones modulate the activation of murine peritoneal macrophages: receptor mediated modulation","volume":"119","author":"Savita","year":"1998","journal-title":"Comp. Biochem. Physiol. C, Pharmacol. Toxicol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0745","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1365-2249.1996.d01-842.x","article-title":"Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells","volume":"106","author":"Kanda","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0750","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1359\/jbmr.1999.14.8.1330","article-title":"The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line","volume":"14","author":"Hofbauer","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0755","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4049\/jimmunol.144.2.499","article-title":"IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro","volume":"144","author":"Guerne","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0760","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1172\/JCI0215704","article-title":"Androgen receptor-mediated inhibition of cutaneous wound healing","volume":"110","author":"Ashcroft","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0765","doi-asserted-by":"crossref","DOI":"10.1002\/pros.23195","article-title":"NF-\u03baB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance","author":"Austin","year":"2016","journal-title":"Prostate."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0770","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-12-0142","article-title":"Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells","author":"Vignozzi","year":"2012","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0775","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1242\/jcs.02786","article-title":"Androgens modulate the inflammatory response during acute wound healing","volume":"119","author":"Gilliver","year":"2006","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0780","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03191116","article-title":"Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals","volume":"33","author":"Duborija-Kovacevic","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0785","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-5793(91)80591-P","article-title":"Molecular cloning and sequence analysis of cDNA encoding \u03944-3-ketosteroid 5\u03b2-reductase of rat liver","volume":"283","author":"Onishi","year":"1991","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0790","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.1021\/bi800572s","article-title":"The crystal structure of human \u03944-3-ketosteroid 5\u03b2-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism","volume":"47","author":"Faucher","year":"2008","journal-title":"Biochemistry."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0795","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.steroids.2014.01.013","article-title":"5\u03b2-Reduced steroids and human \u03944-3-ketosteroid 5\u03b2-reductase (AKR1D1)","volume":"83","author":"Chen","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0800","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cbi.2012.12.012","article-title":"Alternative splicing in the aldo-keto reductase superfamily: implications for protein nomenclature","author":"Barski","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0805","first-page":"5","article-title":"The rate-determining steps of aldo\u2013keto reductases (AKRs), a study on human steroid 5\u03b2-reductase (AKR1D1)","author":"Chen","year":"2014","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0810","article-title":"Differential activity and expression of human 5\u03b2-reductase (AKR1D1) splice variants","author":"Appanna","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0815","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jsbmb.2019.02.002","article-title":"AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells","volume":"189","author":"Nikolaou","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105724","article-title":"The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1","author":"Barnard","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0825","article-title":"Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol","author":"Clark","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2004.11.007","article-title":"3\u03b1,5\u03b2-Reduced cortisol exhibits antagonist properties on cerebral cortical GABA A receptors","author":"Penland","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0835","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.71.6.2290","article-title":"Enhancement of RNA synthesis in avian liver cell cultures by a 5\u03b2 steroid metabolite during induction of \u03b4 aminolevulinate synthase","author":"Incefy","year":"1974","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0840","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI105701","article-title":"Studies on steroid fever: I. Production of leukocyte pyrogen in vitro by etiocholanolone","volume":"47","author":"Bodel","year":"1968","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0845","doi-asserted-by":"crossref","DOI":"10.1172\/JCI106461","article-title":"Studies on steroid fever. II. Pyrogenic and anti-pyrogenic activity in vitro of some endogenous steroids of man","author":"Dillard","year":"1970","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0850","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.58.3.985","article-title":"Stimulation of hemoglobin synthesis in chick blastoderms by certain 5beta androstane and 5beta pregnane steroids","author":"Levere","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0855","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1073\/pnas.65.3.564","article-title":"Erythropoietic activity of steroid metabolites in mice","volume":"65","author":"Gorshein","year":"1970","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0860","doi-asserted-by":"crossref","DOI":"10.1172\/JCI107415","article-title":"Effective erythropoiesis induced by 5\u03b2 pregnane 3\u03b2 hydroxy 20 one in squirrel monkeys","author":"Besa","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0865","doi-asserted-by":"crossref","DOI":"10.1084\/jem.149.6.1314","article-title":"The influence of steroid hormone metabolites on the in vitro development of erythroid colonies derived from human bone marrow*","author":"Urabe","year":"1979","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0870","doi-asserted-by":"crossref","DOI":"10.1093\/molehr\/gah201","article-title":"5\u03b2-Dihydroprogesterone and steroid 5\u03b2-reductase decrease in association with human parturition at term","author":"Sheehan","year":"2005","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0875","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4781(00)00278-5","article-title":"Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme","volume":"1517","author":"Charbonneau","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0880","first-page":"S156","article-title":"5\u03b2-reductase in the human fetal brain","volume":"77","author":"Lisboa","year":"1974","journal-title":"Acta Endocrinol. (Copenh)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0885","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/molehr\/gah201","article-title":"5 Beta-dihydroprogesterone and steroid 5 beta-reductase decrease in association with human parturition at term","volume":"11","author":"Sheehan","year":"2005","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0890","doi-asserted-by":"crossref","first-page":"D84","DOI":"10.1093\/nar\/gkr991","article-title":"Ensembl 2012","volume":"40","author":"Flicek","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0895","doi-asserted-by":"crossref","first-page":"D1093","DOI":"10.1093\/nar\/gkr1177","article-title":"MOPED: model organism protein expression database","volume":"40","author":"Kolker","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0900","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1016\/S0021-9258(18)88899-8","article-title":"The sexually differentiated delta 4-3-ketosteroid 5 beta-reductase of rat liver. Purification, characterization, and quantitation","volume":"260","author":"Mode","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0905","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/neu.10225","article-title":"Brain aromatase, 5\u03b2-reductase, and 5\u03b2-reductase change seasonally in wild male song sparrows: relationship to aggressive and sexual behavior","volume":"56","author":"Soma","year":"2003","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0910","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq1184","article-title":"NCBI GEO: Archive for functional genomics data sets-10 years on","volume":"39","author":"Barrett","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0915","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.metabol.2011.05.001","article-title":"Overexpression of hepatic 5alpha-reductase and 11beta-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients","volume":"60","author":"Baudrand","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.08.004","article-title":"Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase\/reductase isoforms in human livers","author":"Amai","year":"2020","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0925","first-page":"1283","article-title":"3-Oxo-delta 4 bile acids in liver disease","volume":"1","author":"Clayton","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0930","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1172\/JCI113837","article-title":"\u03944-3-oxosteroid 5\u03b2-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis","volume":"82","author":"Setchell","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0935","doi-asserted-by":"crossref","DOI":"10.1111\/cen.12596","article-title":"Distinguishing primary from secondary \u03944-3-oxosteroid 5\u03b2-reductase (SRD5B1, AKR1D1) deficiency by urinary steroid analysis","author":"Yanagi","year":"2015","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0940","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.steroids.2007.12.001","article-title":"Human \u03944-3-oxosteroid 5\u03b2-reductase (AKR1D1) deficiency and steroid metabolism","volume":"73","author":"Palermo","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0945","article-title":"Abnormal low ratio of cholic acid to chenodeoxycholic acid in a cholestatic infant with severe hypoglycemia","volume":"12","author":"Kimura","year":"1991","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0950","first-page":"606","article-title":"Increased urinary excretion of 3-oxo-delta4 bile acids in Japanese patients with idiopathic neonatal cholestasis","volume":"27","author":"Kimura","year":"1998","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0955","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1046\/j.1442-200x.2000.01284.x","article-title":"Abnormally low ratio of cholic acid to chenodeoxycholic acid due to a deficiency of 3-oxo-Delta4-steroid 5beta-reductase","volume":"42","author":"Kimura","year":"2000","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0960","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.52.10.1494","article-title":"Mutations in SRD5B1 (AKR1D1), the gene encoding \u03b4 4-3-oxosteroid 5\u03b2-reductase, in hepatitis and liver failure in infancy","volume":"52","author":"Lemonde","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0965","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jhep.2003.12.024","article-title":"SRD5B1 (AKR1D1) gene analysis in \u03944-3-oxosteroid 5\u03b2-reductase deficiency: evidence for primary genetic defect","volume":"40","author":"Gonzales","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0970","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1440-1746.2008.05669.x","article-title":"SRD5B1 gene analysis needed for the accurate diagnosis of primary 3-oxo-\u0394 4 -steroid 5\u03b2-reductase deficiency","volume":"24","author":"Ueki","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0975","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.3748\/wjg.v18.i47.7113","article-title":"Primary \u03944-3-oxosteroid 5\u03b2-reductase deficiency: two cases in China","volume":"18","author":"Zhao","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0980","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1016\/S0021-9258(17)42821-3","article-title":"Purification and characterization of \u0394-3-Ketosteroid 5\u03b2-Reductase","volume":"259","author":"Okuda","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0985","doi-asserted-by":"crossref","first-page":"19786","DOI":"10.1074\/jbc.C109.016931","article-title":"Inhibition of human steroid 5\u03b2-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex","volume":"284","author":"Drury","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2021.105808_bib0990","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.steroids.2011.01.003","article-title":"Substrate specificity and inhibitor analyses of human steroid 5\u03b2-reductase (AKR1D1)","volume":"76","author":"Chen","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2021.105808_bib0995","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.metabol.2019.153947","article-title":"AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease","volume":"99","author":"Nikolaou","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.jsbmb.2021.105808_bib1000","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/JOE-19-0473","article-title":"Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo","volume":"245","author":"Nikolaou","year":"2020","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib1005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1677\/JOE-09-0003","article-title":"Dysregulation of glucocorticoid metabolism in murine obesity: comparable effects of leptin resistance and deficiency","volume":"201","author":"Livingstone","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2021.105808_bib1010","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.49.EP730","article-title":"Gender specific metabolic phenotype in the 5[beta]-reductase knockout mouse","author":"Gathercole","year":"2017","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.jsbmb.2021.105808_bib1015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2021.105808_bib1020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2017.10.005","article-title":"Dysregulation of \u03944-3-oxosteroid 5\u03b2-reductase in diabetic patients: implications and mechanisms","volume":"470","author":"Valanejad","year":"2018","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076021000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076021000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:06:23Z","timestamp":1760745983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076021000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":204,"alternative-id":["S0960076021000017"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105808","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105808"}}